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The Jewish Ashkenazi Founder Mutations in the
BRCA1/BRCA2 Genes Are Not Found at an Increased
Frequency in Ashkenazi Patients with Prostate Cancer
To the Editor:
BRCA1 and BRCA2, the predisposing genes for breast
cancer (BC) and ovarian cancer (OC), have been sug-
gested to increase the risk of prostate cancer (PrC) in
male carriers (Ford et al. 1994; Thorlacius et al. 1996;
Struewing et al. 1997); however, no direct evidence exists
to confirm this hypothesis. A population with a high
carrier frequency of BRCA1 and BRCA2 germinal mu-
tations allows a direct approach to studying the role
BRCA1 and BRCA2 play in the development of PrC; if
germinal mutations in BRCA1 and BRCA2 increase the
risk of PrC in carriers, it is to be expected that the carrier
frequency in PrC patients will be higher than in the gen-
eral population, as was demonstrated in female patients
diagnosed with BC and OC (Ford et al. 1995; Claus et
al. 1996, Abeliovich et al. 1997).
In the Ashkenazi Jewish population, three founder
mutations, 185delAG and 5382insC in the BRCA1 gene
and 6174delT in the BRCA2 gene, exist at a high fre-
quency (2.5%) (Struewing et al. 1995; Oddoux et al.
1996; Roa et al. 1996; Fodor et al. 1998). To assess the
contribution of the BRCA1/BRCA2 germinal mutations
to PrC morbidity, we analyzed the Ashkenazi founder
mutations in two groups (with the same age distribution)
of Ashkenazi men, a group of unselected PrC patients,
and a control group of men with no history of cancer.
The study was designed around the fact that, in families
known to segregate BRCA1/BRCA2 mutations, men
with PrC were noted sporadically. It was thus assumed
that, if BRCA1 and BRCA2 play a role in the devel-
opment of PrC, they do so as risk modifiers rather than
as major dominant genes, and therefore will not be con-
fined to familial cases.
Patients diagnosed with adenocarcinoma of the pros-
tate ( ) were recruited from the oncology outpa-n = 87
tient clinic at Sharett Institute, Hadassah Hebrew Uni-
versity Hospital, with no preselection. The patients
signed an informed-consent form approved by the hos-
pital’s ethics committee. Each patient was interviewed
regarding his family history. Clinical and pathological
records were the sources of the clinical data.
The control group included 87 healthy men with no
history of cancer. These men were approached in Jeru-
salem-area homes for the elderly and were asked to par-
ticipate in the study; if they agreed, they signed an in-
formed-consent form. Their blood samples were kept
anonymous, labeled only with the patients’ ages and
origins (table 1). The median age was 71 years at the
time of diagnosis for the patients with PrC and 72 years
at the time of blood sampling for the control group (table
2). The mutations were analyzed as described elsewhere
(Abeliovich et al. 1997).
The risk of developing PrC is age-dependent and is
determined by differential exposure to environmental
factors. In addition, positive family history is a major
risk factor for developing PrC at an early age (Steinberg
et al. 1990; Spitz et al. 1991; Whittemore et al. 1995).
It is assumed that ∼10% of all cases of PrC and half of
the cases diagnosed at an early age (!60 years) are dom-
inantly inherited. Linkage analyses in families with mul-
tiple cases of PrC pointed to a PrC-susceptibility gene
(or group of genes) on chromosome 1 (Smith et al. 1996;
Gro¨nberg et al. 1997a; Berthon et al. 1998; Schaid et
al. 1998), and, recently, an X-linked gene was suggested
(Xu et al. 1998). It can be argued that BRCA1 and
BRCA2 markedly reduce the age at onset of PrC and
that therefore the effect of BRCA1/BRCA2 will be
shown only in patients diagnosed with PrC at age !60
years, whereas in our study only five patients were as-
certained in this age group. However, since 2.5% of
Ashkenazi males are BRCA1/BRCA2 carriers, it would
be expected that an excess of Ashkenazi men will de-
velop PrC at age !60 years. The stratification of the ages
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Table 1
Study Group of Ashkenazi Patients with PrC and Control Group: Age at Diagnosis, Cancer History, and the
Ashkenazi BRCA1/BRCA2 Founder Mutations
GROUP
NO. OF SUBJECTS DIAGNOSED OR TESTED
AT AGE (IN YEARS)
GROUP
TOTAL!50 50–59 60–69 70–79 180 Unknown
All subjectsa 1 9 72 142 29 ) 253
PrC study group 1 4 36 38 3 5 87
Carriers ) 1b 1c 1d ) ) 3
Carriers with second primary tumore ) 1 1 ) ) ) 2
Carriers with cancer in family ) ) 1 ) ) ) 1
Noncarriers with second primary tumorf ) ) 4 4 ) 1 9
Noncarriers with cancer in familyg ) 2 10 11 1 2 26
Control group ) 3 27 31 26 3 87
Carriers ) 2h ) 1i ) ) )
a Total number of Ashkenazi patients treated in Sharett Oncology Institute from January 1991 to July 1997.
b Patient A, carrying mutation 185delAG.
c Patient B, carrying mutation 6174delT.
d Patient C, carrying mutation 185delAG.
e Patient A had chronic lymphocytic leukemia; patient B had BC at age 59 years.
f Second primary tumors included melanoma ( ) and tumors of the bladder ( ), lung ( ), rectumn = 3 n = 2 n = 1
( ), and kidney and colon in the same patient.n = 2
g Six patients had first-degree relatives with PrC; eight patients had first-degree relatives with BC, including
one male relative.
h Carriers of mutation 185delAG.
i Carrier of mutation 6174delT.
Table 2








A (5) 5.9 (3) 5.4 (5)
B (35) 13.6 (28) 5.9 (31)
C (27) 32.8 (21) 6.2 (24)
D (12) 37.4 (10) 7.6 (5)
Carrier patients
B (patient Ab) 60 18
B (patient Bc) 47 8
B (patient Cb) 60 7
a In mg/ml.
b Carrier of mutation 185delAG.
c Carrier of mutation 6174delT.
at diagnosis in the study group was similar to that of
PrC patients in Israel, and only rarely are patients di-
agnosed before age 50 years (Israel Cancer Registry,
1994). The data of Struewing et al. (1997) also support
the view that there is no excess of Ashkenazi patients
with PrC diagnosed at age !50 years. They estimated
the risk of cancer among relatives of Ashkenazi carriers
of BRCA1 and BRCA2, which for PrC was 16% (95%
confidence interval [CI] 4%–30%) by age 70 years; by
age 80 years the risk increased to 39%. Interestingly, in
the same study (Struewing et al. 1997), the risk of OC
was 16% by age 70 years (95% CI 6%–28%), similar
to that of PrC. It should be emphasized that, although
BRCA1/BRCA2 are major dominant genes in BC and
in OC and although carriers tend to develop those can-
cers at a young age, 18% of the female patients diag-
nosed at age 50 years with BC or OC were carriers of
BRCA1 or BRCA2—8% of the BC patients and 66%
of the OC patients (Abeliovich et al. 1997).
Three patients in the study group were identified as
mutation carriers: patients A and C with 185delAG
(BRCA1) and patient B with 6174delT (BRCA2). In the
control group, three individuals were identified as car-
riers, two with 185delAG and one with 6174delT (table
1).
Two of the three carrier patients had second primary
tumors: CLL (chronic lymphocytic leukemia) in patient
A, and breast cancer in patient B. Among the noncarrier
patients, 9 (11%) of 84 had a second primary tumor
(including one patient with two second primary tumors).
A history of cancer in first-degree relatives was noted
in patient B: his sister had BC, his father had PrC, and
his son had testicular cancer. The two carrier patients,
A and C, did not have positive family histories (the close
relatives of patient A died in the Holocaust). Cancer
history in first-degree relatives was noted in 26 (31%)
of the 84 patients (table 1); in 5 of these patients the
cancer was PrC, and the mothers of 4 had BC (both the
mother and the daughter of one of these 4 had BC). The
father of 1 patient had BC; the sisters of 2 others had
BC; and the mother of 1 other had OC.
The clinicopathological data of the carrier and non-
carrier patients is given in table 2. The carrier patients
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were diagnosed at ages 57, 62, and 73 years (average
64 years). The average level of prostate serum antigen
(PSA) in the carrier patients was 55.8 mg/ml, higher than
the average (23.6) in noncarrier patients at all stages;
the difference in the PSA level was highly significant
( ). The three carrier patients were diagnosed at2x 1 30
stage B with Gleason scores of 7, 8, and 18, higher than
the average (5.9) for the noncarrier patients at stage B
and similar to the average at stage D. The clinicopath-
ological records of the patients indicated that the tumors
in the three carriers were highly proliferative. This may
suggest that mutations in BRCA1 and BRCA2 may have
some role in the progression of the disease. A similar
observation was made of PrC in patients who belong to
HPC1-linked families (Gro¨nberg et al. 1997b) and in
BRCA1-associated breast cancers (Eisinger et al. 1996;
Marcus et al. 1996; Blackwood and Weber 1998; Rob-
son et al. 1998). However, this conclusion is based on
three patients and should be confirmed in a larger num-
ber of patients.
The frequency of carriers in the study group of PrC
patients and in the group of healthy men was 3.4%
(95% CI 1.48%–5.4%), which is within the range of
the population frequency (2.5%) (Fodor et al. 1998). In
order to detect a minor difference between the two
groups, a much larger sample was needed. Instead, we
chose a different approach in which we calculated the
expected percentage of carriers of BRCA1/BRCA2 foun-
der mutations among the PrC patients, on the basis of
the existent risk figures: 16% by age 70 years and 39%
by age 80 years (Struewing et al. 1997). Assuming that
we follow Ashkenazi men from age 50 years through
age 80 years, we further assumed that the rate of carriers
is 2.5% and that among the carriers the average risk of
developing PrC prior to age 80 years is ∼20%. We would
then expect that every year 33 of 100,000 new Ashke-
nazi patients with PrC would be carriers of any of the
BRCA1/BRCA2 founder mutations. Israeli data show
that the number of new cases among Ashkenazi men at
this age (50–80 years), is ∼260 in 100,000 (Israel Cancer
Registry, 1994); hence the carriers would be ∼13% of
the patients (33/260). We had 87 patients, and therefore
expected 11 carriers in our study group, but observed
3. The difference between the expected and observed
result is highly significant ( in the exact-bi-P ! .0005
nomial test). The size of the sample enables a power of
80% for detecting a difference in carriers of 2.5% in
the control group and at least 12.5% in the patients
group. It is interesting to note that the strong association
found among Israeli females between ethnic origin and
breast cancer is not evident for prostate cancer. The age-
standardized rate of breast cancer among Jewish women
born in Europe or America (i.e., having an Ashkenazi
origin) is 1.57 times that of Jewish women born in North
Africa (non-Ashkenazi origin), whereas the respective
rate for men having prostate cancer is 0.9 (Israel Cancer
Registry, 1994). The age-adjusted rate of PrC (per
100,000) in Israeli Jewish men by place of birth is 32.2
for those born in Europe and North America (Ashkenazi
Jews), 32.5 for men born in Africa and Asia, and 43.5
for men born in Israel (Israel Cancer Registry, 1994).
We therefore suggest that the contribution of BRCA1/
BRCA2 germinal mutations to PrC morbidity is negli-
gible. Our conclusion is in agreement with other studies
in which PrC patients were tested directly (Langston et
al. 1996; Johannesdottir et al. 1996; Wilkens et al. 1999)
and with some of the epidemiological studies (Isaacs et
al. 1995; McCahy et al. 1996). However, our conclusion
contradicts other epidemiological studies (Arason et al.
1993; Ford et al. 1994; Thorlacius et al. 1996; Struewing
et al. 1997), in which the data were based on infor-
mation received about first-degree relatives of carriers,
while the PrC patients themselves were not analyzed. It
would be interesting to explore the possibility of other
sources of variation, such as environmental factors that
affect BRCA1/BRCA2 carriers to a greater extent than
noncarriers and to which men in Israel are not exposed.
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An HFE Intronic Variant Promotes Misdiagnosis of
Hereditary Hemochromatosis
To the Editor:
Hereditary hemochromatosis (HH; MIM 235200), an
autosomal recessive disorder of iron metabolism, can
result in numerous clinical complications and is esti-
mated to affect ∼1/300 individuals of northern European
origin (Merryweather-Clarke et al. 1997). Two muta-
tions—C282Y and H63D—that contribute to HH have
been identified (Feder et al. 1996), and screening for the
C282Y mutation, in particular, is routinely done to iden-
tify carriers and affected individuals. Biochemical mark-
ers indicate a relatively clear distinction between these
two groups, with minimal clinical consequences for het-
erozygotes (Bulaj et al. 1996). We initiated screening for
the C282Y mutation, using the primer sequences pro-
vided by Feder et al. (1996) and subsequent restriction
digestion of PCR products (Jazwinska et al. 1996). Re-
